Plant Cell, Tissue and Organ Culture (PCTOC) 2019;136(3):511522
Substancje, ktre nie zostay zatwierdzone jako leki lub wyroby medyczne, sprzedawane s na terenie Unii Europejskiej jako materia referencyjny
Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon
Aug 2017;23(2):79-84
While clinical trials show significant weight loss with standard dosing protocols, evidence on very low or microdosed regimens remains limited
Licensed healthcare professionals evaluate each patient to determine eligibility and create personalized treatment plans focused on safe, sustainable weight loss and metabolic health
